M. Popescu

TL;DR: The increased rate of HBsAg clearance in patients with HBeAg-negative chronic hepatitis B supports the use of peginterferon alpha-2a as a first-line treatment.

TL;DR: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon α-2a and/or lamivudine.

TL;DR: Analysis of data from a large, randomized, multinational phase III registration trial involving 271 HBV‐infected HBeAg‐positive patients who received peginterferon alfa‐2a plus oral placebo suggests quantitative HBe Ag is a useful adjunctive measurement for predicting H beAg seroconversion in patients treated with peginters when considering both sensitivity and specificity compared with serum HBV DNA.

TL;DR: Peginterferon alfa-2a results in increasing rates of HBsAg clearance during post-treatment follow-up in HBeAg-negative patients and on-treatment decline is significantly associated with long-term post- treatment response.

TL;DR: Low HBsAg levels during peginterferon alfa-2a therapy were associated with high rates of posttreatment response, and on-treatment HBs Ag quantification may help guide patient management in the future.